A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

Kazuaki Taguchi, Toshikazu Miyakawa, Takafumi Ohmura, Momoko Horio, Yoshihisa Anraku, Tatsuya Okada, Hiroshi Mizuta, Hideyuki Saito, Tatsuya Kawaguchi

研究成果: Article査読

7 被引用数 (Scopus)

抄録

The optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic-pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.

本文言語English
ページ(範囲)77-80
ページ数4
ジャーナルScandinavian Journal of Infectious Diseases
45
1
DOI
出版ステータスPublished - 2013 1月
外部発表はい

ASJC Scopus subject areas

  • 免疫学および微生物学一般
  • 微生物学(医療)
  • 感染症

フィンガープリント

「A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル